Invivyd’s (IVVD) “Buy” Rating Reiterated at D. Boral Capital

D. Boral Capital reiterated their buy rating on shares of Invivyd (NASDAQ:IVVD) in a research note published on Thursday,Benzinga reports. They currently have a $9.00 price objective on the stock.

A number of other research firms also recently issued reports on IVVD. Morgan Stanley decreased their price objective on Invivyd from $9.50 to $3.55 and set an “overweight” rating for the company in a report on Wednesday, November 20th. EF Hutton Acquisition Co. I upgraded shares of Invivyd to a “strong-buy” rating in a report on Wednesday, October 30th. Finally, HC Wainwright cut their price objective on shares of Invivyd from $15.00 to $10.00 and set a “buy” rating on the stock in a research report on Wednesday, November 20th. Four analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the company has a consensus rating of “Buy” and an average target price of $7.89.

Invivyd Price Performance

IVVD opened at $0.72 on Thursday. The company has a market capitalization of $86.57 million, a price-to-earnings ratio of -0.36 and a beta of 0.65. The business’s 50-day moving average price is $0.97 and its two-hundred day moving average price is $1.22. Invivyd has a 1 year low of $0.69 and a 1 year high of $5.20.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in IVVD. Barclays PLC increased its holdings in Invivyd by 179.6% during the third quarter. Barclays PLC now owns 117,973 shares of the company’s stock worth $120,000 after buying an additional 75,780 shares during the last quarter. State Street Corp increased its stake in shares of Invivyd by 3.7% during the 3rd quarter. State Street Corp now owns 1,018,640 shares of the company’s stock worth $1,039,000 after purchasing an additional 35,904 shares during the last quarter. Proficio Capital Partners LLC bought a new stake in shares of Invivyd in the 3rd quarter valued at about $27,000. Cubist Systematic Strategies LLC raised its holdings in shares of Invivyd by 66.1% in the 2nd quarter. Cubist Systematic Strategies LLC now owns 134,452 shares of the company’s stock valued at $148,000 after purchasing an additional 53,499 shares during the period. Finally, Susquehanna Fundamental Investments LLC acquired a new stake in Invivyd in the 2nd quarter valued at about $115,000. Institutional investors and hedge funds own 70.36% of the company’s stock.

Invivyd Company Profile

Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering.